financetom
Business
financetom
/
Business
/
Oracle Health, Ci4CC Enter Partnership to Advance AI in Oncology Care
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Oracle Health, Ci4CC Enter Partnership to Advance AI in Oncology Care
Nov 7, 2025 8:04 AM

10:28 AM EST, 11/07/2025 (MT Newswires) -- Oracle's (ORCL) Oracle Health and Life Sciences unit said Friday it is collaborating with the Cancer Center Informatics Society, or Ci4CC, to support artificial intelligence innovation in oncology care and research.

The partnership will combine Oracle's technology with Ci4CC's Initiatives Program and network of cancer centers to design an electronic health record optimized for cancer care, the company said.

The collaboration will focus on integrating clinical and genomic data, developing AI-driven tools for clinical trials and drug discovery, and creating precision oncology and real-world evidence platforms, Oracle added.

Price: 236.48, Change: -7.33, Percent Change: -3.00

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sunrun Likely to Offer Longer-Term Demand Visibility Due to US Treasury Guidance, RBC Says
Sunrun Likely to Offer Longer-Term Demand Visibility Due to US Treasury Guidance, RBC Says
Aug 18, 2025
08:01 AM EDT, 08/18/2025 (MT Newswires) -- Sunrun ( RUN ) is likely to offer longer-term demand visibility due to the US Treasury outlook, which will also help the company largely eliminate the uncertainty under President Trump's executive order for stringent Treasury guidance on enforcement of commerce construction rules, RBC said in a Monday note. The company's value proposition lies...
DallasNews Files Proxy Statement for Proposed Buyout by Hearst
DallasNews Files Proxy Statement for Proposed Buyout by Hearst
Aug 18, 2025
08:03 AM EDT, 08/18/2025 (MT Newswires) -- DallasNews ( DALN ) said Monday it has filed a definitive proxy statement for its proposed acquisition by Hearst. Under Hearst's proposal, DallasNews ( DALN ) shareholders will receive $15 per share in cash, implying a premium of 242% over the company's last class A share price close of $4.39 before the proposal...
Aptose Biosciences Reports Early Positive Tuspetinib Safety Data Across Newly Diagnosed AML Patients
Aptose Biosciences Reports Early Positive Tuspetinib Safety Data Across Newly Diagnosed AML Patients
Aug 18, 2025
08:01 AM EDT, 08/18/2025 (MT Newswires) -- Aptose Biosciences ( APTOF ) on Monday said the latest data update from the Phase 1/2 Tuscany trial in newly diagnosed acute myeloid leukemia (AML) patients show no significant safety concerns with different dose levels of the company's lead candidate, tuspetinib. The trial was initiated last December. Data from 10 patients across all...
Soligenix Says Dusquetide Gets Orphan Drug Designation From US FDA to Treat Behcet's Disease
Soligenix Says Dusquetide Gets Orphan Drug Designation From US FDA to Treat Behcet's Disease
Aug 18, 2025
08:04 AM EDT, 08/18/2025 (MT Newswires) -- Soligenix ( SNGX ) said Monday that the US Food and Drug Administration has granted orphan drug designation to dusquetide for the treatment of Behcet's disease, an inflammatory disorder of the blood vessels. The decision was made after a review of the recent phase 2a clinical results showing biological efficacy and safety in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved